• A thin curvilinear opacity, typically a few millimeters or less in thickness, situated less than 1 cm from the pleural surface and running parallel to it.

• This finding can be observed in various conditions, including dependent atelectasis, pulmonary edema, and fibrosis.
• In the context of interstitial lung disease, it can be an early indicator of fibrotic changes.
• It may represent the confluence of thickened interlobular septa and intralobular interstitial thickening.

Hansell DM, Radiology, 2008

• An abnormal displacement of pulmonary structures such as bronchi, vessels, fissures, or septa.
• This disruption of normal anatomy is often a result of localized or diffuse lung disease, particularly interstitial fibrosis.

• This is a key feature of pulmonary fibrosis, where scarring processes exert traction on the surrounding parenchyma, leading to the displacement of normal structures.
• It is frequently accompanied by other signs of fibrosis such as traction bronchiectasis and volume loss.
• Its presence is a significant finding and is strongly associated with conditions like idiopathic pulmonary fibrosis (IPF) and fibrotic non-specific interstitial pneumonia (NSIP).

Lynch DA, The Lancet Respiratory Medicine, 2018

• Irreversible and irregular dilatation of bronchi and bronchioles that occurs within areas of pulmonary fibrosis.

• This finding is caused by the pulling (traction) force of surrounding fibrotic lung tissue.
• It is considered a strong indicator of fibrosis and is a key feature of the Usual Interstitial Pneumonia (UIP) pattern.
• The presence and severity of traction bronchiectasis are associated with worse clinical outcomes and increased mortality in patients with interstitial lung abnormalities.

Hida T, European Journal of Radiology, 2020

• This presentation refers to localized fibrosis (scarring) at the base of one lung, identified by subpleural lines and architectural distortion on imaging.
• The primary clinical significance of this finding is that it typically represents the stable consequence of a prior localized insult, rather than an active, progressive interstitial lung disease (ILD).
• This pattern strongly shifts the diagnostic focus away from idiopathic diseases (like IPF) and toward identifying a specific, localized cause, which is often a historical event like a severe infection or ongoing issue like aspiration.

• This pattern is most commonly the end result of a previous localized insult to the lung. The list of potential causes is narrow compared to that for bilateral fibrosis.
• Post-Infectious Scarring: Often considered the most common cause, a prior severe pneumonia (bacterial or fungal) or tuberculosis can heal by forming fibrous scar tissue, leaving permanent architectural distortion in the affected area.
• Chronic Aspiration: Recurrent microaspiration, often silent and related to gastroesophageal reflux disease (GERD), can cause chronic, low-grade inflammation leading to localized fibrosis. This process frequently affects the right lung base due to common sleeping postures.
• Other Localized Causes: Less common possibilities include radiation-induced fibrosis (which is strictly confined to a prior treatment port), localized lung trauma, or chronic atelectasis (incomplete lung expansion).

• The underlying mechanism is completed healing after a significant, one-time inflammatory injury (e.g., severe pneumonia) or the result of chronic, low-grade injury (e.g., aspiration).
• Following the injury, damaged lung tissue is replaced by scar tissue (collagen).
• Unlike progressive ILDs such as IPF, this is often a static, “burnt-out” scar, not an ongoing, self-perpetuating fibrotic process. The distinction is critical, as inflammation may resolve, but fibrosis is generally permanent.

• The result is a localized area of scarring with volume loss, architectural distortion (warped or displaced bronchi and vessels), and traction bronchiectasis. The rest of the lung parenchyma is typically normal.
• High-Resolution Computed Tomography (HRCT) is essential to confirm the unilateral nature of the findings and characterize the scarring.
• The primary role of imaging is to differentiate this pattern from a typical ILD and to search for ancillary clues to the specific cause, such as esophageal dilation (suggesting aspiration) or localized bronchiectasis from a prior infection.

• Many patients may be asymptomatic, with the finding being incidental. If symptoms are present, they typically include a nonproductive cough or shortness of breath on exertion.
• Functional impairment may be minimal or mild. Pulmonary function tests (PFTs) might be normal or show a slight restrictive pattern, depending on the extent of the scar.
• Workup is guided by clinical suspicion. If aspiration is suspected, tests to evaluate for GERD may be performed. A broad autoimmune panel is generally not high-yield unless other clinical signs of a connective tissue disease are present.
• Reviewing prior imaging is critical to establish stability over time, which strongly supports a post-inflammatory cause.

• Management: Treatment is directed at the underlying cause, not the scar itself. If the fibrosis is stable and from a past infection, no specific treatment is required. If chronic aspiration is the cause, management focuses on anti-reflux measures.
• Antifibrotic medications (e.g., nintedanib, pirfenidone) are not indicated for stable, unilateral scarring. Their use is reserved for diagnosed *progressive* fibrosing diseases.
• Prognosis: The prognosis is generally excellent and non-progressive if the finding represents a stable scar from a past, resolved event. It does not carry the poor prognosis associated with IPF, which has a median survival of 3-5 years. If the cause is ongoing (like aspiration), the prognosis depends on the successful management of that underlying condition.

• The term “fibrosis” originates from the Modern Latin “fibra” (fiber) and the Greek suffix “-osis” (a condition), describing the formation of scar tissue.
• “Post-inflammatory” or “post-infectious” are prefixes used to signify that the fibrosis is a stable, residual consequence of a previous inflammatory event (like pneumonia or aspiration) rather than an ongoing, active disease process.
• The term “pneumonitis” refers to inflammation of the lung tissue. In the context of aspiration, it is a chemical injury, not an infection. The subsequent fibrosis is the healing response to this injury.

• Post-Infectious Scarring: A general term for fibrosis that remains after a lung infection, such as severe pneumonia or, classically, tuberculosis, has resolved.
• Aspiration Pneumonitis Sequelae: This refers to the chronic fibrotic changes that can develop in the lungs, often in the dependent lower lobes, as a result of single or recurrent aspiration of foreign material, most commonly stomach contents.
• Mendelson’s Syndrome: While this term, coined in 1946, specifically describes the acute, severe chemical pneumonitis from aspirating gastric acid, its historical importance lies in identifying aspiration as a major cause of lung injury that can lead to chronic fibrosis.
• Cirrhosis of the Lung: An early, general descriptive term for any condition that resulted in hardened, scarred lungs.
• Post-inflammatory Fibrosis: A broad term indicating that the scarring is the end result of a resolved inflammatory process, whatever the cause.

• The understanding that severe lung infections could lead to permanent scarring predates the modern classification of interstitial lung diseases. For centuries, “consumption” (tuberculosis) was known to leave behind cavities and fibrotic scars in the lungs of survivors.
• A pivotal moment in understanding a non-infectious cause of inflammatory fibrosis came in 1946, when obstetrician Curtis Lester Mendelson published his landmark paper on gastric acid aspiration during anesthesia in childbirth. This established a clear link between a single inflammatory event and subsequent lung damage, including fibrosis.
• Historically, the main tool for assessing this damage was the chest X-ray, which could show coarse, stable opacities.
• The advent of High-Resolution Computed Tomography (HRCT) was a major advance, allowing clinicians to precisely characterize the features of post-inflammatory scarring (e.g., architectural distortion, traction bronchiectasis) and, crucially, to differentiate it from the patterns of active, progressive fibrosing diseases like IPF.

• The recognition that unilateral or focal fibrosis often represents a “scar” from a prior event rather than an active “disease” represents a fundamental diagnostic pivot. It shifts the focus from managing a progressive disease to investigating a past insult.
• This concept places immense value on the patient’s history. Questions about prior severe pneumonia, tuberculosis, radiation therapy, or symptoms of acid reflux become critical clues to solving the diagnostic puzzle.
• The historical understanding of aspiration risk, as highlighted by Mendelson, directly led to the widespread cultural practice in medicine of requiring patients to have “Nil per os” (nothing by mouth) for several hours before receiving anesthesia to prevent this complication.
• The modern approach is not to label all fibrosis as a problem, but to determine if the fibrosis is stable (a scar) or progressive (an active disease). This distinction, often made with serial imaging, has profound implications for prognosis and treatment.

• Curtis Lester Mendelson (1913-2002): An American obstetrician whose 1946 study on 66 women who aspirated stomach contents during anesthesia was a seminal work. He clearly described the acute chemical pneumonitis that could result and established aspiration as a primary cause of severe, localized lung inflammation that could lead to chronic fibrosis.
• René Laennec (1781-1826): The inventor of the stethoscope, Laennec was a pioneer in correlating clinical sounds with autopsy findings. His detailed descriptions of the lung damage caused by tuberculosis, including cavitation and scarring (“phthisis”), laid the groundwork for understanding post-infectious pulmonary fibrosis.
• William Osler (1849-1919): A foundational figure in modern medicine, his use of the general term “chronic interstitial pneumonia” in his influential textbook encompassed many conditions, including the fibrotic consequences of prior inflammation.

• A key teaching axiom: “Not all fibrosis is IPF. Much of it is just a scar.” This emphasizes the need to differentiate stable, post-inflammatory scarring from active, progressive fibrosing lung disease.
• “The first question in unilateral or focal fibrosis is: What was the insult?” This line directs the diagnostic process toward a search for a specific, localized cause like infection, aspiration, or radiation.
• “Scars are memories of a battle won; active fibrosis is a war still being fought.” This conceptual line distinguishes the static nature of a post-inflammatory scar from the dynamic process of a progressive fibrotic disease.
• “The lung has a limited and predictable response to injury; thus, a variety of disease processes may produce similar imaging findings.” This classic line remains crucial, underscoring why a patient’s history is essential to interpret the fibrotic pattern seen on a CT scan.

A Poem for a Scar

Where fever burned or silent reflux crept,
A lung once fought a battle while you slept.
The fight is over, the invader gone,
A quiet scar remains to greet the dawn.

No creeping shadow of a dread disease,
But just a memory etched among the trees
Of bronchi pulled and pathways slightly bent,
A static map of where the war was spent.

This is no thief that steals the breath away,
But healed-up land where trouble came to stay,
Then left its mark, a fibrous, lasting trace,
A settled peace within that single space.

• Why the correct answer is correct:
• Myofibroblasts are the primary effector cells responsible for synthesizing and depositing large quantities of extracellular matrix proteins (like collagen). This is the final common pathway for scar formation, whether from a progressive disease like IPF or a static, post-inflammatory scar.
• Why the incorrect answers are incorrect:
• Alveolar macrophages and neutrophils are inflammatory cells involved in the initial injury and signaling, but they are not the primary producers of the scar matrix itself.
• Type II pneumocytes are involved in the repair process after injury, but the myofibroblast is the main cell type that directly deposits the fibrotic tissue.

• Why the correct answer is correct:
• Fibrosis, even when localized, makes that portion of the lung stiff and reduces its volume. If the scarring is significant enough, it will result in a measurable reduction in overall lung volumes (FVC, TLC) and impair gas exchange (DLCO), leading to a restrictive pattern. If scarring is minimal, PFTs can be normal.
• Why the incorrect answers are incorrect:
• An obstructive pattern (decreased FEV1/FVC) is characteristic of diseases like asthma or COPD, not fibrosis.
• Fibrosis leads to decreased, not increased, lung volumes and diffusing capacity.
• While PFTs can be normal in very mild, focal scarring, they are not expected to be normal if the fibrosis is “significant.”

• Why the correct answer is correct:
• Demonstrating stability over time is the single most crucial factor. If the fibrosis is unchanged over 2+ years, it strongly suggests a static, “burnt-out” scar from a past insult (e.g., old infection). This carries an excellent prognosis. Any sign of progression would change the diagnosis and prognosis.
• Why the incorrect answers are incorrect:
• Ground-glass opacity and elevated CRP are non-specific signs of inflammation and do not define the long-term behavior of the scar.
• While smoking is a risk factor for many lung diseases, it does not determine the prognosis of an established focal scar.

• Why the correct answer is correct:
• If the fibrosis is stable and asymptomatic, it represents a permanent scar, not an active disease. No treatment is needed for the scar itself. The focus is on observation and addressing any potential ongoing causes (like treating acid reflux if aspiration is suspected) to prevent further injury.
• Why the incorrect answers are incorrect:
• Antifibrotics and corticosteroids are treatments for progressive or inflammatory lung diseases, respectively. They are not indicated for a stable, “burnt-out” scar and have significant side effects.
• Surgical resection would be overly aggressive and unnecessary for asymptomatic, stable scarring.

• Why the correct answer is correct:
• Architectural distortion is a core sign of fibrosis. It is defined by the abnormal displacement of normal structures like bronchi, vessels, and fissures, which are pulled out of place by the traction of surrounding scar tissue.
• Why the incorrect answers are incorrect:
• (a) describes ground-glass opacity. (c) describes honeycombing. (d) describes a subpleural line. While honeycombing and subpleural lines are features of fibrosis, they are not the definition of architectural distortion itself.

• Why the correct answer is correct:
• A unilateral pattern is the key feature that points away from systemic or idiopathic diseases (which are typically bilateral) and toward a localized insult. The fibrosis is confined to the area of the original injury (e.g., the part of the lung affected by a past pneumonia or recurrent aspiration).
• Why the incorrect answers are incorrect:
• IPF and other systemic ILDs are almost always bilateral. A purely unilateral pattern makes these diagnoses highly unlikely.
• Chronic HP can be patchy but is typically bilateral.

• Why the correct answer is correct:
• The lower lobes are the most dependent portions of the lungs, making them the most common sites for both aspiration-related injury and for community-acquired pneumonia. Therefore, post-inflammatory scarring from either of these causes is a top consideration for fibrosis in this location.
• Why the incorrect answers are incorrect:
• The other options are incorrect because their typical distribution does not match the finding. Sarcoidosis favors the upper lobes, while asbestosis and most drug-induced lung injuries are bilateral and diffuse.